Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd (SHA:600671)
China flag China · Delayed Price · Currency is CNY
14.75
-0.30 (-1.99%)
Nov 18, 2026, 3:00 PM CST

SHA:600671 Revenue

Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd had revenue of 50.43M CNY in the quarter ending September 30, 2026, a decrease of -8.88%. This brings the company's total for the last twelve months to 202.59M, down -19.46% year-over-year. In the year 2025, Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd had annual revenue of 211.75M, down -2.55%. That makes Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd the 31,311th largest company in the world by revenue and 5,008th in China.

Revenue (ttm)
202.59M
Revenue Growth
-19.46%
P/S Ratio
9.05
Revenue / Employee
516.82K
Employees
392
Market Cap
1.80B

Revenue Chart

Revenue by Segment

  • Health Care Products 90.99M 43.0%
  • Circulating Commodities 50.35M 23.8%
  • Active Pharmaceutical Ingredient (API) 30.30M 14.3%
  • Chinese Patent Medicine 28.26M 13.3%
  • Service Type 5.19M 2.5%
  • Medical Instruments 3.79M 1.8%
  • Chemical Medicine 1.84M 0.9%
  • Other 979.71K 0.5%
Fiscal year ended Dec 31, 2025 See the full SHA:600671 breakdown

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 2025211.75M-5.54M-2.55%
Dec 31, 2024217.30M95.52M78.44%
Dec 31, 2023121.78M12.87M11.82%
Dec 31, 2022108.91M-38.16M-25.95%
Dec 31, 2021147.07M-59.56M-28.82%
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.